BioSpace News Archive

Preclinical and clinical data on anti-BKV monoclonal antibody MAU868 highlights promise of ongoing clinical development program for transplant patients

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces that the first patient has been dosed in its Phase 1 trial evaluating FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137

Kidney disease is a public health crisis and the National Kidney Foundation is calling on the Biden-Harris Administration to make it a top priority during their first 100 days in office.

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module

i2O Therapeutics, an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc.

Today, Infinity BiologiX (IBX), a leading next-generation central laboratory providing sample collection and processing, storage, analytical services, and scientific and technical support, announced the latest addition to its executive team, naming Amit Bhalla as Vice President and Chief Financial Officer.

Combination transforms Luna into a global fiber optic leader; creates a distributed fiber sensing powerhouse Acquisition combines two global leaders in fiber optic sensing solutions OptaSense’s market-leading position in distributed acoustic sensing (DAS) combined with Luna’s suite of sensing products forms the industry’s most comprehensive portfolio

Presentation to Highlight the Company’s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from Dec. 9-12, 2020

Nonin Medical, a global leader in noninvasive medical monitoring, has been named to Inc.'s inaugural Best in Business list in the Health Products category.